Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. This is done using engineered autologous cell therapy (eACT). The engineered T cells are designed to recognize and destroy cancer cells. Kite anticipates potential launch and commercialization of its first lead product (KTE-C19) in 2017.
Santa Monica, US
185 (est)+85%

Kite Pharma Locations

Santa Monica, US
Seattle, US
Washington, US
Boston, US
Orlando, US
Cincinnati, US
Houston, US
New York, US
Detroit, US
Omaha, US
El Segundo, US
Raleigh, US
Chicago, US
San Francisco, US
Atlanta, US

Kite Pharma Metrics

Kite Pharma Summary

Founding Date


Market capitalization

$2.18 B

Closing share price


Kite Pharma Market Value History

Kite Pharma Online Presence

Kite Pharma News

Kite Pharma Company Life